# Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

> **NCT06574698** · — · RECRUITING · sponsor: **Guangzhou Women and Children's Medical Center** · enrollment: 64 (estimated)

## Conditions studied

- Neuroblastoma
- GD2 Antibody (Naxitamab)

## Interventions

- **DRUG:** Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

## Key facts

- **NCT ID:** NCT06574698
- **Lead sponsor:** Guangzhou Women and Children's Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-06
- **Primary completion:** 2029-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06574698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06574698, "Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06574698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*